TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07602582: An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 550 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$15,757,456

Rescue Site Savings

+$10,413,144

Unlock Full NCT07602582 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07602582 Rescue Dossier →